BCG 백신 시장 : 연령층별, 용도별, 최종 용도별, 예측(2024-2032년)

Global BCG Vaccines Market will demonstrate 5.4% CAGR between 2024 and 2032, attributed to the high prevalence of Tuberculosis worldwide. The ongoing global burden of Tuberculosis, particularly in developing countries, fuels the demand for BCG vaccines.

According to WHO, an estimated 10.6 million people contracted TB globally in 2022, up from 10.3 million in 2021 and 10.0 million in 2020, marking a continued reversal of the previously sustained downward trend up to 2020. Similarly, the Tuberculosis incidence rate (new cases per 100,000 population per year) is assessed to have risen by 1.9% between 2020-2021 and 2021-2022. As more people fall ill with TB, especially in high-risk regions, governments and health organizations intensify immunization efforts. This heightened focus on TB prevention through vaccination significantly contributes to the growth of the BCG vaccines market.

The overall BCG vaccines industry is segregated based on age group, application, end-use, and region.

The adults segment will garner appreciable gains throughout 2024-2032. The demand for BCG vaccines among adults is favored by several factors, including the rise in TB cases and the need for protection in high-risk populations, such as healthcare workers and those with weakened immune systems. In addition, the BCG vaccine's potential therapeutic use in bladder cancer treatment has increased its demand among adults. Heightened awareness about TB prevention and the benefits of vaccination further encourage adult immunization. Moreover, global travel and migration expose more adults to TB-endemic regions, prompting vaccination as a preventive measure. Public health initiatives and recommendations by health organizations also play a significant role in driving adult BCG vaccination.

The bladder cancer segment could stimulate the application landscape of the BCG vaccines market over 2024-2032, propelled by the proven efficacy of BCG vaccines in treating non-muscle invasive bladder cancer (NMIBC). BCG therapy significantly reduces the risk of cancer recurrence and progression by stimulating the immune system to attack cancer cells. Clinical studies and long-term patient outcomes support its effectiveness, making it a standard treatment option. Additionally, increasing bladder cancer incidence rates and the need for cost-effective, non-surgical treatment options drive demand. Ongoing research and positive clinical trial results further validate BCG's therapeutic benefits in bladder cancer, encouraging widespread adoption in medical practice.

North America BCG vaccines market will amass a modest valuation by 2032 due to the rising incidence of Tuberculosis among vulnerable populations and increased awareness of TB prevention. Strong government support and funding for immunization programs ensure widespread vaccine availability and distribution. Additionally, the growing recognition of BCG vaccines' role in treating non-muscle invasive bladder cancer drives their adoption in oncology. Advanced healthcare infrastructure, robust research and development activities, and stringent regulatory standards further support market growth. Public health campaigns and recommendations from health organizations like the CDC reinforce the importance of BCG vaccination, contributing to the market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing incidence of tuberculosis (TB)
    • 3.2.1.2 Surge in R&D investments
    • 3.2.1.3 Rising awareness and adoption of vaccination programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Vaccine shortages and supply chain challenges
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
• 3.7 Expanding applications of BCG vaccines
• 3.8 Pricing analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Pediatrics
• 5.3 Adults

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Tuberculosis
• 6.3 Bladder cancer

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Clinics

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 India
  • 8.4.2 China
  • 8.4.3 Indonesia
  • 8.4.4 Philippines
  • 8.4.5 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AJ Biologics Sdn Bhd
• 9.2 BCG Vaccine Laboratory
• 9.3 Biomed Lublin S.A.
• 9.4 GSBPL
• 9.5 Japan BCG Laboratory
• 9.6 Merck & Co., Inc.
• 9.7 Microgen
• 9.8 Serum Institute of India Pvt. Ltd.
• 9.9 Taj Pharmaceuticals Limited
• 9.10 Zydus Group